11/20
08:07 am
orgo
Organogenesis (NASDAQ:ORGO) had its price target raised by analysts at BTIG Research from $7.00 to $9.00. They now have a "buy" rating on the stock.
Low
Report
Organogenesis (NASDAQ:ORGO) had its price target raised by analysts at BTIG Research from $7.00 to $9.00. They now have a "buy" rating on the stock.
11/8
01:17 pm
orgo
High
Report
11/7
04:38 pm
orgo
Organogenesis Holdings Inc. (ORGO) Q3 2025 Earnings Call Transcript [Seeking Alpha]
High
Report
Organogenesis Holdings Inc. (ORGO) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/6
04:05 pm
orgo
Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance
High
Report
Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance
11/3
01:10 pm
orgo
Organogenesis Applauds CMS’s Significant Step In Payment Reform
Low
Report
Organogenesis Applauds CMS’s Significant Step In Payment Reform
10/31
04:59 pm
orgo
Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Medium
Report
Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
10/31
04:05 pm
orgo
Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/28
10:00 am
orgo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
10/23
10:00 am
orgo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
10/18
10:00 am
orgo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
10/17
02:20 pm
orgo
Organogenesis Holdings Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ORGO
Low
Report
Organogenesis Holdings Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ORGO
10/13
01:50 pm
orgo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
Neutral
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
10/8
04:36 pm
orgo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
10/1
04:05 pm
orgo
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025
Low
Report
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025
9/29
08:28 am
orgo
Organogenesis: Mixed ReNu Data, But Policy Tailwinds And Growth Remain Bullish [Seeking Alpha]
Low
Report
Organogenesis: Mixed ReNu Data, But Policy Tailwinds And Growth Remain Bullish [Seeking Alpha]
9/26
08:05 am
orgo
Organogenesis (NASDAQ:ORGO) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $7.00 price target on the stock.
Medium
Report
Organogenesis (NASDAQ:ORGO) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $7.00 price target on the stock.
9/25
05:00 pm
orgo
Organogenesis Provides Update on Second Phase 3 ReNu® Study [Yahoo! Finance]
Medium
Report
Organogenesis Provides Update on Second Phase 3 ReNu® Study [Yahoo! Finance]
9/25
04:50 pm
orgo
Organogenesis Provides Update on Second Phase 3 ReNu® Study
High
Report
Organogenesis Provides Update on Second Phase 3 ReNu® Study